目的：观察玻璃体腔内注射康柏西普治疗近视性脉络膜新生血管(myopic choroid neovascularization，mCNV)的疗效。

方法：回顾性分析2013-01/2016-12于湖南省人民医院眼科诊断为mCNV的患者15例16眼的临床资料，根据病情行玻璃体腔注射康柏西普1次或1次以上，治疗后随访1.5～28mo，观察患者治疗前后最佳矫正视力(BCVA)和黄斑区视网膜厚度的变化。

结果：本研究纳入患者15例16眼，均行玻璃体腔注射康柏西普治疗，其中6眼治疗1次，7眼治疗2次，3眼治疗3次，重复注射者每次治疗时间间隔均为1mo。治疗前平均眼压(16.44±1.39mmHg)和治疗后末次随访时(16.75±1.41mmHg)比较，差异无统计学意义(P>0.05)。治疗后末次随访时BCVA(0.71±0.21)较治疗前(1.14±0.35)显著改善，差异有统计学意义(P<0.05)。治疗后末次随访时黄斑区视网膜厚度(287.25±30.31μm)较治疗前(361.63±33.59μm)降低，差异有统计学意义(P<0.05)。治疗及随访期间，未出现眼内炎、脑卒中、视网膜脱离等严重并发症或不良反应。

结论：玻璃体腔内注射康柏西普能在短期内改善mCNV患者的视力，有利于减少黄斑中心凹视网膜厚度，且并发症较少，临床应用相对安全。

METHODS: The study was a retrospective analytical case series. We reviewed medical records of 15 patients(16 eyes)with choroidal neovascularization second to high myopia that had enrolled in our hospital from January 2013 to December 2016. All patients have received one or more conbercept injections based on medical condition and observed the best corrected visual acuity(BCVA)and macular retinal thickness before and after the last injection. The duration of the last follow-up was from 1.5mo to 28mo.

RESULTS: Totally 15 patients(16 eyes)were enrolled in this study. All patients received conbercept injections. Among all the patients, 6 eyes were given one treatment, 7 eyes were given two treatments and 3 eyes three treatments. Before retreatment, the mean intraocular pressure was 16.44±1.39mmHg before treatment, and the average intraocular pressure was 16.75±1.41mmHg after the last treatment. The difference was not statistically significant(P>0.05). BCVA was 1.14±0.35 before treatment, BCVA was 0.71±0.21 at the last follow-up. The difference was statistically significant(P<0.05). The thickness of the macular retina was 361.63±33.59μm before treatment, and it was 287.25±30.31μm at the last follow-up, and the difference was statistically significant(P<0.05). And there was no case of endophthalmitis, stroke, and retinal detachment during follow-up.

CONCLUSION: Intravitreal injection of conbercept can effectively improve the patient's BCVA in the short term and reduce the macular fovea retinal thickness. No significant adverse events are observed.